QIAGEN acquisition of STAT-Dx Life, S.L.
Acquisition31/01/2018
QIAGEN announced an agreement to acquire STAT-Dx, developer of a multiplex molecular-diagnostics platform. Its 2018 annual report identifies STAT-Dx Life, S.L. as the legal target and confirms acquisition of all shares on April 27, 2018. The technology became QIAstat-Dx.
Type
Acquisition
Announced
31/01/2018
Amount
Financial data requires access
Reported parties
QIAGEN N.V.; STAT-Dx Life, S.L.